In Situ Gene Therapy for Prostate Cancer: Development of Systemic Anti-Tumor Immunity
Annual rept. 31 Dec 2001-30 Dec 2002
BAYLOR COLL OF MEDICINE HOUSTON TX
Pagination or Media Count:
Although to our knowledge there are no dearly defined tumor antigens for prostate cancer, based on our preliminary data we of the opinion that specific gene-modified cell-based immunotherapy protocols could result in the generation of a systemic anti-metastatic immune response. We have shown that IL-12B7 transduced antigen-presenting cells APC can effectively induce an anti-tumor immunity that IL-12B7 modified prostate cancer cell vaccine strategies can generate a systemic anti-tumor immune response and, that IL-12B7 gene delivery has specific therapeutic effects against bone metastases. We proposed to test the efficacy of specific therapeutic approaches incorporating novel biological concepts of IL-12 gene modified cell-based therapy using preclinical models of metastatic prostate cancer.
- Genetic Engineering and Molecular Biology
- Medicine and Medical Research